Invasiveness of cancer cells is associated with proliferation inhibition in multiple types of 33 cancers. Here, we identified the pivotal roles of Arginine methyltransferase PRMT7 in 34 promoting invasion and attenuating proliferation of breast cancer cells. PRMT7 exerted its 35 functions through binding to the scaffold protein shank2 to induce the di-methylation of shank2 36 at R240. Shank2 R240 methylation exposed ANK domain by disrupting its SPN-ANK domain 37 blockade. Moreover, shank2 R240 methylation rendered recruitment of FAK that elicited the 38 FAK auto-phosphorylation, which consequently augmented the shank2-dependent migration 39 and invasion of breast cancer cells. On the other hand, the shank2 R240 methylation impeded 40 proliferation of breast cancer cells by antagonizing the Ras-Raf binding via tethering the 41 mono-ubiquitinated H-Ras. These findings characterize the PRMT7-dependent shank2 42 methylation as a key player in mediating reciprocal switching between invasion and 43 proliferation, also point to the value of shank2 R240 methylation as a target for tumour 44 metastasis treatment strategies.
171
Arginine methylation of shank2 is upregulated in clinical breast cancer samples 172 Previous reports showed that the expression of shank2 in head and neck cancer tissues was 173 higher than that in adjacent tissues, and this upregulation was correlated with the survival 174 rate and prognosis of patients (Qin et al., 2016) . According to the Human Protein Atlas 175 database, the expression of shank2 in breast cancer samples is higher than that in the 176 adjacent tissues (Figure 2A ). We also observed that shank2 mRNA was highly expressed in 177 human breast tumours ( Figure 2B ). To investigate the clinical relevance of shank2 178 methylation, a direct western blot analysis of breast cancer tumours (T) and their adjacent 179 normal tissues (N) was performed, and the results demonstrated that shank2 was 180 overexpressed in human breast cancer tumours, and was remarkably hypermethylated in 181 cancerous tissues, with a corresponding activation of shank2 ( Figure 2C ). This analysis 182 revealed a positive correlation between shank2 di-methylation and neoplastic tissue.
183
Together, these data indicate that upregulated shank2 expression and its elevated To further identify the methylation site of shank2 in breast cancer cells, we performed mass 188 spectrometric analysis of methylation of shank2 in malignant breast cancer cell MDA-MB-231 189 that overexpressed Rat HA-shank2 (a gift from Dr. Min Goo Lee) . We detected that the 190 arginine 240 residue (R240) of shank2 was di-methylated ( Figure 3A ). Using sequence 191 homology comparison, we found that the R240 residue is evolutionarily conserved ( Figure   192 3B). Then we constructed a shank2 mutation with R240 residue replaced by lysine (shank2 193 R240K) to test the effect of shank2 R240 methylation. We found that shank2 di-methylation 194 was decreased in shank2 R240K, whereas shank2 WT did not affect the di-methylation level 195 ( Figure 3C,D) . We then overexpressed increasing doses of PRMT7 in HEK293T cells, and 196 we found that shank2 R240 di-methylation level was increased accordingly ( Figure 3E , 
199
Next, we intended to study the effects of shank2 di-methylation on breast cancer cells. 
209
MMP2/MMP9 activation and the migration/invasion capabilities of MDA-MB-231 cells were 210 also inhibited by shank2 depletion, and in both cases the inhibition was abrogated by 211 reconstituted expression of shank2 WT but not by shank2 R240K ( Figure 3H -K, Figure   212 3-figure supplements 2E-F). Together, these results strongly support the assumption that 213 shank2 di-methylation is a crucial factor controlling EMT, migration and invasion 214 characteristics of breast cancer cells.
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R240 methylation disturbs SPN-ANK domain blockade of shank2
217
To explore the mechanism of shank2 function in breast cancer cell migration and invasion,
218
we studied the conformational changes of wild-type shank2 (WT) and its mutant (R240K) by 219 using molecular dynamics simulations. As shown in Figure 4A , the SPN domain in shank2 220 R240K mutant needs more energy to reach an "open" state than that in shank2 WT,
221
according to the free energy profile. The trajectory for the window with the global minimum 222 free energy (the distance between SPN and ANK is 31.5 Å, the SPN and ANK domains were 223 represented in different colours in Figure 4B ) in WT and the one (the distance between SPN 224 and ANK is 30 Å) in R240K were analysed. The average number of hydrogen bonds between 9 the two domains was 0.96±0.05 in each frame of WT. The most hydrogen bonds were formed 226 in N100/R227 and E119/K260 for the locations of these residues ( Figure 4C ). After R240 was 227 mutated to K, two domains formed 1.57±0.02 hydrogen bonds in D97/K229, Y140/H192,
228
N100/R227, Y140/N190 and S256/E119 for the locations of mentioned residues ( Figure 4D ).
229
Thus, structural analyses suggest that shank2 R240K mutants not only possess a more 230 stable energy fluctuation, but also form more hydrogen bonds, causing the loss of 231 appropriate space for insertion of partner proteins. 238 structural changes, we used mass spectrometry to find the possible regulatory factors. Our 239 mass spectrometric data showed that shank2 could interact with proteins in integrin signalling 240 pathway, including β1-integrin, Talin, FAK, EEA1 and cortactin. To test this, we conducted 241 Co-IP assays to determine that Talin, FAK and shank2 were in the same complex in analysis found that shank2 also bind to H-Ras. To validate this, we first investigated shank2 273 interact with H-Ras WT ( Figure 6A demonstrated that the interaction between shank2 and H-Ras was significantly increased by 280 reconstituted expression of shank2 WT but not shank2 R240K ( Figure 6E ). Of note, the 281 11 PRMT7-dependent methylation did not affect Rabex5 and RIN1 binding to shank2 ( Figure   282 6C-E). Moreover, in MCF7 cells, suppression of shank2 or overexpression of shank2 R240F, 283 a methylation mimic, but not shank2 WT, dramatically increased H-Ras binding ability to 284 Rabex5 and RIN1 ( Figure 6F ). Consistently with this observation, in vitro His pulldown assay 285 showed that PRMT7 knockdown decreased and shank2 knockdown increased H-Ras 
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To determine whether shank2 is involved in regulation of H-Ras activation, we examined The above findings intrigued us to test the functions of shank2 in the pathological progression 304 of breast cancer. To assess the biological effect of shank2 in vivo, we examined whether 305 shank2 di-methylation affects tumour growth and metastasis in xenograft mouse models. We The invasive ability of cancer cells is correlated with the attenuation of cell proliferation in a 322 number of cancer cell lines, tumour models, and at the invasive front of human melanoma, 323 colorectal and breast cancer (Gil-Henn et al., 2013; Hur et al., 2016; Patsialou et al., 2015) .
324
PRMTs, such as PRMT1, CARM1, PRMT5, PRMT6 and PRMT7, tend to be upregulated metastasis are yet to be elucidated. Previously we reported that PRMT7 attenuates breast 329 cancer cells proliferation during the process of metastasis (Yao et al., 2014) . In this study, we (Lilja et al., 2017) . In contrast to shank1 and shank3, the present study 350 reveals that shank2, especially the methylated shank2, is correlated with high level of 351 incidence of breast cancer ( Figure 2C ). Our data demonstrate that methylated shank2 352 promotes breast cancer metastasis ( Figure 7D,E) . We also identify the interaction between Figure 6L ), and this is presumably the mechanism that switches tumour cells from 377 proliferation into a dormancy state. Our data implicate that the PRMT7-mediated shank2 378 methylation may be a critical mediator of dormancy tumour. Shank2 R240 methylation and its 379 downstream effectors could also be targeted to reduce the risk of cancer recurrence in breast 380 cancer patients.
381
In conclusion, data presented in this report outline a working model in which PRMT7 382 regulates breast tumour metastasis and growth by methylation of shank2, a new substrate of 
